U.S. News compares companies to their industry peers based on a variety of company fundamentals, performance metrics and investor preferences to help you find the right stocks for your investing style ...

Class-action lawsuits are underway against Hims & Hers Health Inc., representing investors who bought or acquired company securities between April 29, 2025, and June 23, 2025. The lawsuit alleges that ...

Use code YANKS2025 for 10% off your next SeatGeek order*: <a href=" Sponsored by SeatGeek. *Restrictions apply. Max $20 ...

The healthcare outsourcing market is expanding rapidly worldwide, and the Philippines, with more than 200,000 remote professionals, is playing a key role ...

Hims & Hers Health, Inc. (NYSE: HIMS) is one of the best Russell 2000 stocks to buy now. On August 18, Truist Securities ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.4% in the afternoon session after investors took some ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Copycat versions of popular drugs like Ozempic and Mounjaro have continued to proliferate in a postshortage era, with some ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Novo Nordisk shares (DK:NOVO.B) (NVO) rose 5% in opening New York trade. The American depository receipts however have plunged 37% this year amid increased competition for its weight-loss drugs as ...